Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs iShares Core S&P 500 ETF (IVV) Price & Performance

Citius Pharmaceuticals IncTrade
iShares Core S&P 500 ETFTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs iShares Core S&P 500 ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.71 (market cap $20.01M), while iShares Core S&P 500 ETF trades at $775.99. The key difference: iShares Core S&P 500 ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CTXRIVV
Market Cap
$20.01M
Sector
HealthBroad Market / Factor
52-Week High
$1.82$776.81
52-Week Low
$0.48$634.93
Enterprise Value
$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

iShares Core S&P 500 ETF

IVV, tracking the S&P 500, trades at $776.38, down slightly by 0.04% amid broader market caution ahead of inflation data. The ETF shows a bullish technical signal with moving averages supporting upside, but oscillators are neutral and RSI levels indicate overbought conditions. Recent news highlights institutional interest, with First Bank & Trust increasing its stake, while JPMorgan raised its S&P 500 target to 8,000 for 2026, citing strong earnings and AI-driven growth (JPMorgan report, August 10, 2026).

Outlook remains positive due to robust corporate earnings and AI investments, but risks include high valuations and potential pullbacks from overbought levels. Investors should weigh the ETF's diversification benefits against market volatility and economic data sensitivity.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.

Read more on IVV